Goldfarb Branham LLP is investigating whether executives at Mela Sciences (NASDAQ: MELA) breached their legal duties to shareholders through their public statements about MelaFind. Concerned Mela Sciences investors are urged to contact securities lawyer Hamilton Lindley to ask about their rights and remedies at 877-583-2855 or email@example.com.
“A class action lawsuit has been filed that alleges Mela and certain executives deceived investors about MelaFind and its prospects for FDA approval while defendants were selling almost $79 million in stock,” said securities attorney Hamilton Lindley. “The complaint alleges that when the truth was revealed on November 16, 2010, the stock plummeted 46% on heavy trading volume.”
Goldfarb Branham LLP represents shareholders and whistleblowers nationwide and has been appointed by courts to serve as lead counsel on behalf of shareholders in high profile securities litigation. The firm represents clients at no cost or liability to investors. For more information about this situation, please contact the firm at 877-583-2855 or